Core Viewpoint - The company, Jindike (688670.SH), reported a revenue increase of 7.18% year-on-year, but still faced a net loss, indicating challenges in profitability despite revenue growth [1] Financial Performance - The company achieved an operating revenue of 3.5242 million yuan, reflecting a year-on-year increase of 7.18% [1] - The net profit attributable to the parent company was -39.6531 million yuan, showing a year-on-year reduction in losses by 2.97% [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -42.9408 million yuan, with a year-on-year reduction in losses of 8.92% [1] Market Opportunity - The domestic penetration rate of quadrivalent influenza vaccines is significantly lower than that of foreign markets, indicating substantial growth potential [1] - The company aims to capitalize on the steady growth of the influenza vaccine market in China by ensuring product quality and actively pursuing sales transformation [1] - The sales strategy focuses on deepening market penetration, enhancing service to end users, and expanding the incremental market to increase market share in the influenza vaccine sector [1]